U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H25N3O
Molecular Weight 287.3999
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROXAZOLE

SMILES

CCC(C1=NOC(CCN(CC)CC)=N1)C2=CC=CC=C2

InChI

InChIKey=OLTAWOVKGWWERU-UHFFFAOYSA-N
InChI=1S/C17H25N3O/c1-4-15(14-10-8-7-9-11-14)17-18-16(21-19-17)12-13-20(5-2)6-3/h7-11,15H,4-6,12-13H2,1-3H3

HIDE SMILES / InChI

Description

Proxazole or 3-alpha-Phenyl-propyl-5-beta-diethylaminoethyl-1,2,3-oxadiazole is a drug used for functional gastrointestinal disorders. It’s an unusual drug because it possesses both anti-inflammatory and antispasmodic properties and because each of these two properties has some uncommon features. The antiinflammatory action takes place mostly against edematous responses and is devoid of ulcerogenic effects which are instead produced by most anti-inflammatory drugs; moreover proxazole prevents indomethacin-induced ulcers without exerting any anti-secretory effect. The antispasmodic activity results in a specific inhibition of smooth muscle spasm, both at the vascular and at the intestinal level, without significant interferences with the physiologic activity of that tissue.

Originator

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
oral: 400 mg proxazole (5.2--6.5 mg/kg/day)
Route of Administration: Other
In Vitro Use Guide
Unknown